WO2009125987A3 - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation Download PDF

Info

Publication number
WO2009125987A3
WO2009125987A3 PCT/KR2009/001833 KR2009001833W WO2009125987A3 WO 2009125987 A3 WO2009125987 A3 WO 2009125987A3 KR 2009001833 W KR2009001833 W KR 2009001833W WO 2009125987 A3 WO2009125987 A3 WO 2009125987A3
Authority
WO
WIPO (PCT)
Prior art keywords
drugs
pharmaceutical formulation
present
compartment
release
Prior art date
Application number
PCT/KR2009/001833
Other languages
French (fr)
Korean (ko)
Other versions
WO2009125987A2 (en
WO2009125987A9 (en
Inventor
김성욱
전성수
조영관
구자성
선상욱
김정택
이아람
최진원
장석영
김병하
김진욱
남태영
이길호
Original Assignee
한올제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한올제약주식회사 filed Critical 한올제약주식회사
Publication of WO2009125987A2 publication Critical patent/WO2009125987A2/en
Publication of WO2009125987A3 publication Critical patent/WO2009125987A3/en
Publication of WO2009125987A9 publication Critical patent/WO2009125987A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical formulation containing an extended-release compartment having a dihydropyridine calcium channel blocker and an immediate-release compartment having an angiotensin-2 receptor blocker. The present invention provides the pharmaceutical formulation in which the dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker are separately contained in each compartment and of which release is controlled. Since each different drug contained in each different compartment of the formulation is released at a different time, the pharmaceutical formulation of the present invention minimizes the antagonism and side effects between drugs and maximizes the specific effect of the drugs. The pharmaceutical formulation by the specific combination between the two drugs according to the present invention has remarkably good effects in treating or preventing diseases compared with the single administration of each of the drugs or the simple combined administration of the drugs.
PCT/KR2009/001833 2008-04-10 2009-04-09 Pharmaceutical formulation WO2009125987A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080033363 2008-04-10
KR10-2008-0033363 2008-04-10

Publications (3)

Publication Number Publication Date
WO2009125987A2 WO2009125987A2 (en) 2009-10-15
WO2009125987A3 true WO2009125987A3 (en) 2009-12-03
WO2009125987A9 WO2009125987A9 (en) 2010-01-28

Family

ID=41162400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001833 WO2009125987A2 (en) 2008-04-10 2009-04-09 Pharmaceutical formulation

Country Status (1)

Country Link
WO (1) WO2009125987A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111956624A (en) * 2020-08-31 2020-11-20 珠海润都制药股份有限公司 Olmesartan medoxomil tablet and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022385A (en) * 1997-08-29 2001-03-15 실버스타인 아써 에이. Combination therapy comprising amlodipine and a statin compound
KR20070078625A (en) * 2006-01-27 2007-08-01 씨제이 주식회사 Multiple unit type sustained release oral formulation and process for the preparation thereof
KR20080016801A (en) * 2005-06-27 2008-02-22 다이이찌 산쿄 가부시키가이샤 Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
KR20080018841A (en) * 2006-08-24 2008-02-28 한올제약주식회사 Controlled release complex formulation comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022385A (en) * 1997-08-29 2001-03-15 실버스타인 아써 에이. Combination therapy comprising amlodipine and a statin compound
KR20080016801A (en) * 2005-06-27 2008-02-22 다이이찌 산쿄 가부시키가이샤 Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
KR20070078625A (en) * 2006-01-27 2007-08-01 씨제이 주식회사 Multiple unit type sustained release oral formulation and process for the preparation thereof
KR20080018841A (en) * 2006-08-24 2008-02-28 한올제약주식회사 Controlled release complex formulation comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors

Also Published As

Publication number Publication date
WO2009125987A2 (en) 2009-10-15
WO2009125987A9 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
MY153027A (en) Combined preparation for the treatment of cardiovascular diseases based on chronotheraphy theory
WO2009134079A3 (en) Pharmaceutical formulation
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
WO2012016698A3 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
WO2011157416A3 (en) Transdermal administration of memantine
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
EP2526934A3 (en) Inhibitors of bruton's tyrosine kinase
WO2008070346A3 (en) Methods for treating pain with reduced nuasea and vomiting
WO2009127922A3 (en) Pharmaceutical formulation for treating cardiovascular disease
DE502005005636D1 (en) Spirocyclische cyclohexan-derivate
WO2008128740A8 (en) Titration of tapentadol
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2008016677A3 (en) Preparation and utility of deuterated amphetamines
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2010127205A3 (en) Fixed dose drug combination formulations
WO2011159100A2 (en) Anti-cancer pharmaceutical composition
WO2012158030A3 (en) Drug delivery system
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2009068708A8 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
WO2010098627A3 (en) Pharmaceutical preparation
NO20064783L (en) Solution tablets with licarbazepine
WO2009086077A3 (en) A1 adenosine receptor antagonists
WO2009125987A3 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09730462

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09730462

Country of ref document: EP

Kind code of ref document: A2